To evaluate the frequency of bone marrow suppression Adverse Drug Reactions (ADRs) in patients with BRCA mutated HER2 negative high recurrent risk breast cancer treated with LYNPARZA for adjuvant treatment in the actual post-marketing use.
To evaluate the frequency of bone marrow suppression Adverse Drug Reactions (ADRs) in patients with BRCA mutated HER2 negative high recurrent risk breast cancer treated with LYNPARZA for adjuvant treatment in the actual post-marketing use. This investigation will be conducted for application for re-examination specified in Article 14-4 of the Pharmaceutical Affairs Law.
Study Type
OBSERVATIONAL
Enrollment
61
Research Site
Incidence of bone marrow suppression
Time frame: from baseline to 1year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Aichi, Japan
Research Site
Akita, Japan
Research Site
Aomori, Japan
Research Site
Chiba, Japan
Research Site
Ehime, Japan
Research Site
Fukui, Japan
Research Site
Fukuoka, Japan
Research Site
Gifu, Japan
Research Site
Gunma, Japan
Research Site
Hiroshima, Japan
...and 29 more locations